Oct 29, 7:06 AM ET
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million and diluted earnings per share of $3.02, reflecting growth compared to the prior-year period. Driven by strong execution in its Proprietary Products segment, the company raised its full-year net sales and adjusted-diluted EPS guidance ranges.
- Q3 2026 net sales reached $874.5 million, up 8.7% year-over-year, with diluted EPS of $3.02.
- Full-year 2026 net sales guidance was increased to a range of $3.41 billion to $3.42 billion.
- Full-year 2026 adjusted-diluted EPS guidance was raised to a range of $9.38 to $9.48.
- The company repurchased $231 million of stock in the third quarter, bringing year-to-date repurchases to $685 million.
Read the filing on SEC.gov ↗
Oct 26, 5:14 PM ET
On October 26, 2026, West Pharmaceutical Services entered a new credit agreement with Bank of America as administrative agent. It includes a $750 million revolving facility and a $200 million term loan advanced on the effective date, and the company used the borrowings to repay $130.0 million outstanding under its 2019 credit agreement, which it terminated with no early termination penalties. The filing reports no change to earnings or guidance, but it sets new debt terms, including a maximum net leverage ratio of 3.50 to 1.0.
- New credit agreement provides a $750 million revolving facility and a $200 million term loan, with a five-year term from October 26, 2026.
- $130.0 million outstanding under the 2019 credit agreement was repaid in full on October 26, 2026, with no early termination penalties.
- Borrowings are unsecured; the net leverage covenant caps the ratio at 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods.
- Term loan quarterly amortization starts March 31, 2028, at $1.25 million to $2.5 million per quarter, with the balance due at maturity.
Read the filing on SEC.gov ↗
Jul 23, 7:14 AM ET
West Pharmaceutical Services reported second-quarter 2026 net sales of $872.3 million, up 13.8%, and diluted EPS of $2.15, up 18.1%. The company raised its full-year 2026 net sales guidance to $3.345 billion to $3.380 billion and its adjusted-diluted EPS guidance to $8.85 to $9.05, which suggests stronger expected profitability for shareholders.
- Q2 2026 net sales of $872.3 million rose 13.8%; organic growth was 12.7%, led by HVP Components at $424.1 million, up 19.4%.
- Q2 diluted EPS was $2.15, up from $1.82; adjusted-diluted EPS was $2.37, up 28.8%.
- Full-year 2026 adjusted-diluted EPS guidance rose to $8.85 to $9.05 from $8.40 to $8.75.
- Q3 2026 adjusted-diluted EPS guidance is $2.14 to $2.24, and Q3 net sales are expected at $820 million to $835 million.
Read the filing on SEC.gov ↗
Jul 14, 4:29 PM ET
West Pharmaceutical Services entered into an amended and restated crosslicense agreement and two distributorship agreements with Daikyo Seiko, effective July 14, 2026, which the company says are substantially similar to the 2017 agreements as amended in 2018 and 2019. West holds a 49% ownership interest in Daikyo, and the filing describes the agreements as sharing know-how and granting licenses for pharmaceutical packaging and delivery components, with each agreement running 10 years.
- Agreements are effective July 14, 2026 and each has a 10-year term
- West is the exclusive distributor of Daikyo products outside Japan, subject to limited exceptions
- Daikyo is a non-exclusive distributor of West products in Japan
- Full agreement texts will be filed as redacted exhibits to the 10-Q for the quarter ending September 30, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
